Jobs that won’t need humans. Significant loss of jobs. Disruption. Yes, AI will change everybody’s job, but it won’t eliminate them. Let's flip the script: It's not replacement, but transformation. In a world where AI can help doctors provide better care, reach more patients, and work more efficiently... it doesn't sound so bad! Go to the Life of Flow podcast channel and watch the full episode #92 with Dr. William E. Cohn!
AI could be the lifeline to medicine. At least, we're expecting to. Medicine is hard. Really hard. Doctors are drowning in endless hours, packed EDs, work volume, and administrative overload. The profession is at a breaking point. Without tools to make it manageable, there will be no incentive for the next generation to choose medicine. Is the profession at risk of losing the very people who keep it alive? 👀 Go to the Life of Flow podcast channel to hear the full discussion with Dr. William E. Cohn in episode #92!
Big visions demand time, energy, and dedication, but they’re worth it. They need people, too. So how do you bring them together? Go to the Life of Flow podcast channel and watch the full episode #92 with Dr. William E. Cohn!
The first artificial heart in a human 🫀 Haskell Karp survived just four days - but his case marked a monumental leap in medical history. A risky, groundbreaking procedure that forever changed cardiac surgery. Go to the Life of Flow podcast channel and watch the full episode #92 with Dr. William E. Cohn!
Entrepreneurship isn’t a side hustle. Your ideas deserve your full attention, curiosity, and commitment. But you also have to think smart. Don’t sell yourself short on other people’s projects. That’s where mentorship comes in: learn from someone who’s already walked the path. The road to success isn’t easy, and not everyone knows how to navigate it. Learn from someone who does. Go to the Life of Flow podcast channel and watch the full episode #91 with Dr. Mahmood Razavi.
What’s better: having someone buy your ideas, or partnering with you to build them? Now imagine getting paid $2,000 for an idea that later helps a company sell for $450 million. That kind of moment turns into a lesson many innovators learn too late. We talk about the price of intellectual capital, why you should value it as much as financial investment, and how to build relationships that last beyond a single check in our latest episode. Go to the Life of Flow podcast channel and watch the full episode #91 with Dr. Mahmood Razavi.
Choosing the right people to collaborate with can make or break you. Some partners bring credibility, some bring influence, and a few will bring chaos (if you’re not careful!) This week, we go over the cost of the wrong partnership, how to evaluate potential collaborators, and how to identify the right ones with Dr. Mahmood Razavi. Go to the Life of Flow podcast channel and watch the full episode #91 with Dr. Mahmood Razavi.
Want to know where medicine will be in 20 years? Follow the money. Specifically, where the NIH puts its dollars. Much of what’s now standard care began as federally funded research decades ago. Many of today’s billion-dollar therapies began as taxpayer-funded studies. But as of now, that same research investment is being questioned and cut. In this episode, we unpack the real ROI of public science, why pharma’s biggest wins often trace back to NIH discoveries, and what happens if that chain breaks with Dr. Mahmood Razavi. Go to the Life of Flow podcast channel and watch the full episode #91 with Dr. Mahmood Razavi.
How much can patience (and belief in the body’s capacity to heal) change the outcome? In limb preservation, the willingness not to give up too soon can mean the difference between loss and recovery. Tell the truth, share with the patient the risks and the odds... and still, commit to every possible effort. Go to the Life of Flow podcast channel and watch the full episode #90.
Every disruptive therapy comes with a fight. For DVA, that story was LimFlow, which built a new care paradigm, created new codes, and compelled the field to view “no-option” patients in a completely different light. Now, after two years off the market in Europe, LimFlow is back with next-gen stents and crossing devices. Access expands, adoption grows, and the debate gets louder: do we keep DVA only for “no-option” patients, or is it time to start treating poor-option cases too? Go to the Life of Flow podcast channel and watch the full episode #90.